Stuart S Winter Selected Research

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)

1/2022	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
6/2021	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia.
1/2021	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
10/2020	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
12/2019	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children.
6/2019	Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
12/2018	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
10/2018	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
10/2018	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
1/2018	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stuart S Winter Research Topics

Disease

26	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 02/2006
26	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 02/2006
12	Neoplasms (Cancer) 01/2022 - 02/2006
6	Leukemia 01/2021 - 11/2009
4	Residual Neoplasm 01/2018 - 11/2009
3	Hypersensitivity (Allergy) 01/2021 - 02/2006
2	Lymphoma (Lymphomas) 01/2022 - 03/2013
2	Central Nervous System Diseases (CNS Diseases) 01/2022 - 10/2020
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2016 - 01/2011
1	Hypoxia (Hypoxemia) 01/2018
1	Multiple Myeloma 01/2018
1	Disease Progression 05/2013
1	Aspergillosis 01/2011
1	Fungemia 01/2011
1	Neutropenia 01/2011
1	Febrile Neutropenia 01/2011
1	Disease Resistance 12/2008
1	Infections 07/2008
1	Hemoglobinopathies 11/2006
1	Tumor Lysis Syndrome 07/2006
1	Neuroblastoma 07/2006
1	Acute Kidney Injury (Acute Renal Failure) 07/2006
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2006

Drug/Important Bio-Agent (IBA)

7	pegaspargase (Oncaspar)FDA Link 01/2021 - 02/2006
5	Transcription Factors (Transcription Factor)IBA 01/2021 - 08/2006
5	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 02/2006
4	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 07/2009
4	Pharmaceutical PreparationsIBA 01/2018 - 10/2007
3	nelarabine (506U78)FDA Link 10/2020 - 07/2015
3	CytokinesIBA 06/2019 - 03/2013
3	Adenosine Triphosphate (ATP)IBA 05/2013 - 03/2008
2	Proteasome InhibitorsIBA 01/2022 - 03/2010
2	Propofol (Diprivan)FDA LinkGeneric 01/2022 - 01/2003
2	Proteins (Proteins, Gene)FDA Link 06/2021 - 05/2013
2	AntigensIBA 01/2021 - 11/2009
2	Asparaginase (Elspar)FDA Link 01/2021 - 02/2006
2	Leucovorin (Folinic Acid)FDA Link 10/2020 - 10/2018
2	ElementsIBA 12/2019 - 06/2016
2	Cytokine Receptors (Cytokine Receptor)IBA 06/2019 - 03/2013
2	Phosphotransferases (Kinase)IBA 01/2018 - 03/2013
2	Oxygen (Dioxygen)IBA 01/2018 - 11/2006
2	Vincristine (Oncovin)FDA LinkGeneric 05/2013 - 03/2008
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 05/2013 - 03/2008
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 05/2013 - 04/2008
1	Bortezomib (Velcade)FDA Link 01/2022
1	Nitrous Oxide (Laughing Gas)IBA 01/2022
1	ChromatinIBA 06/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	HLA-DQB1 antigen (HLA DQB1)IBA 01/2021
1	Polycomb Repressive Complex 2IBA 12/2018
1	methylervineIBA 10/2018
1	daratumumabIBA 01/2018
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	immunotoxin HA22IBA 11/2017
1	ruxolitinibIBA 01/2017
1	IntegrinsIBA 06/2016
1	Adenosine Monophosphate (AMP)IBA 06/2016
1	CaspasesIBA 06/2016
1	Integrin alpha4beta1 (VLA-4)IBA 06/2016
1	Carrier Proteins (Binding Protein)IBA 06/2016
1	Cyclic AMP (AMP, Cyclic)IBA 06/2016
1	calcein AMIBA 05/2013
1	multidrug resistance-associated protein 1IBA 05/2013
1	Adenosine Triphosphatases (ATPase)IBA 05/2013
1	GuanosineIBA 03/2013
1	Indicators and Reagents (Reagents)IBA 01/2011
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2011
1	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2011
1	Fluconazole (Zonal)FDA LinkGeneric 01/2011
1	Molecular Chaperones (Chaperone, Molecular)IBA 03/2010
1	Gamma Secretase Inhibitors and ModulatorsIBA 03/2010
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 03/2010
1	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 03/2010
1	Histone Deacetylases (Histone Deacetylase)IBA 03/2010
1	CD34 Antigens (CD34 Antigen)IBA 11/2009
1	AntibodiesIBA 11/2009
1	Protein Isoforms (Isoforms)IBA 12/2008
1	TESIBA 07/2008
1	Prednisolone (Predate)FDA LinkGeneric 03/2008
1	Daunorubicin (Cerubidine)FDA LinkGeneric 03/2008
1	hemoglobin ChicoIBA 11/2006
1	RNA (Ribonucleic Acid)IBA 08/2006
1	OligonucleotidesIBA 08/2006
1	rasburicase (Elitek)FDA Link 07/2006
1	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 02/2006
1	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2006
1	AsparagineIBA 02/2006

Therapy/Procedure

19	Therapeutics 01/2022 - 01/2005
15	Drug Therapy (Chemotherapy) 01/2022 - 10/2007
2	Immunotherapy 01/2022 - 01/2018
2	Induction Chemotherapy 08/2010 - 07/2006
1	Cranial Irradiation 10/2018
1	Intramuscular Injections 01/2018
1	Intravenous Infusions 01/2018
1	Aftercare (After-Treatment) 05/2012
1	Catheters 07/2008